|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-3-1
|
|
pubmed:abstractText |
Basic fibroblast growth factor (bFGF) serves as a modulator of survival in breast cancer cells. The mechanisms by which bFGF transduces the anti-apoptotic signal and interacts with COX inhibitors were investigated. bFGF reduced apoptosis in MCF-7 breast cancer cells and up-regulated the expression of mitocondrial Bcl-2, whereas COX inhibitors meloxicam (selective COX-2) and aspirin (non-selective), induced apoptosis. bFGF up-regulated survivin protein expression and induced cdc-2 phosphorylation moderately at early (2-6 h), and substantially at late (24 h), time-points. Survivin mRNA expression was up-regulated only at the later time-point. COX inhibitors prevented up-regulation of survivin protein expression at both 2 and 24 h and prevented early modest increases in cdc-2 phosphorylation. Up-regulation of survivin mRNA was not found to be modulated by the COX-2 inhibitor meloxicam. bFGF regulation of survivin expression was found to be ERK1/2 kinase dependent and bFGF-induced phosphorylation of c-raf was prevented by the COX-2 inhibitor. bFGF was, however, unable to induce COX-2 protein expression or modulate COX-2 activity in MCF-7 cells as evidenced by unaltered PGE(2) production. These results indicate that bFGF regulates survivin expression in MCF-7 breast cancer cells by signaling through an ERK1/2 dependent pathway. COX-2 inhibitors can modulate bFGF-induced survivin expression in a COX-2 independent manner.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CDC2-CDC28 Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/CDK2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 2,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Microtubule-Associated Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazines,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/meloxicam
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0730-2312
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
796-807
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14991771-Apoptosis,
pubmed-meshheading:14991771-Aspirin,
pubmed-meshheading:14991771-Breast Neoplasms,
pubmed-meshheading:14991771-CDC2-CDC28 Kinases,
pubmed-meshheading:14991771-Cell Division,
pubmed-meshheading:14991771-Cell Line, Tumor,
pubmed-meshheading:14991771-Cell Survival,
pubmed-meshheading:14991771-Cyclin-Dependent Kinase 2,
pubmed-meshheading:14991771-Cyclooxygenase 2,
pubmed-meshheading:14991771-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:14991771-Cyclooxygenase Inhibitors,
pubmed-meshheading:14991771-Cytoprotection,
pubmed-meshheading:14991771-Fibroblast Growth Factor 2,
pubmed-meshheading:14991771-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:14991771-Humans,
pubmed-meshheading:14991771-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:14991771-Isoenzymes,
pubmed-meshheading:14991771-MAP Kinase Signaling System,
pubmed-meshheading:14991771-Membrane Proteins,
pubmed-meshheading:14991771-Microtubule-Associated Proteins,
pubmed-meshheading:14991771-Mitochondria,
pubmed-meshheading:14991771-Mitogen-Activated Protein Kinases,
pubmed-meshheading:14991771-Neoplasm Proteins,
pubmed-meshheading:14991771-Phosphorylation,
pubmed-meshheading:14991771-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:14991771-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:14991771-Thiazines,
pubmed-meshheading:14991771-Thiazoles
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells.
|
|
pubmed:affiliation |
Department of Surgery, St. Vincent's University Hospital and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
